1. Introduction {#sec1}
===============

T cell deplete allogeneic stem cell transplantation (AlloHSCT) is frequently complicated by non-infective and infective lung complications. Infective lung complications include cytomegalovirus (CMV) pneumonitis, which usually presents with cough, dyspnoea and increasing hypoxia associated with systemic reactivation of CMV infection. The radiological pattern on high resolution computed tomography (HRCT) is variable but most commonly shows widespread bilateral ground glass infiltrates [@bib1], [@bib2]. Organising pneumonia is an uncommon non-infective respiratory complication of T cell deplete AlloHSCT. It can be idiopathic or it can occur as a complication of infection, radiotherapy or drug therapy [@bib3], [@bib4], [@bib5]. In organising pneumonia, HRCT usually demonstrates patchy subpleural consolidation with no particular lobar or zonal predominance [@bib6]. Treatment with systemic corticosteroids is usually highly effective [@bib7], [@bib8]. Here we describe five cases of CMV pneumonitis affecting AlloHSCT recipients (patient characteristics shown in [Table 1](#tbl1){ref-type="table"}) complicated by a probable organising pneumonia with a distinctive clinical and radiological course.

1.1. Case series {#sec1.1}
----------------

### 1.1.1. Patient 1 {#sec1.1.1}

A 28 year old female non-smoker received a T deplete matched unrelated donor AlloHSCT for refractory Hodgkin\'s lymphoma. On day +25 post-AlloHSCT, serum polymerase chain reaction (PCR) indicated systemic reactivation of CMV with a blood viral load that reached a maximum of 55000 copies/ml by day +39 and a CRP of 50 mg/L (normal range 0--5). This was associated with progressive dyspnoea and an oxygen saturation of 86% on air. HRCT on day +39 showed a bilateral symmetrical ground glass infiltrate with interlobular septal thickening compatible with a viral pneumonitis \[[Fig. 1](#fig1){ref-type="fig"}A(i)\]. CMV PCR viral load in bronchoalveolar lavage (BAL) fluid obtained on day +43 was 3400 copies/ml; microbiological and cytology tests for other pathogens were negative. After treatment with intravenous foscarnet the patient became apyrexial and the blood CMV viral load negative, with no clinical evidence of active infection. However, the patient remained dyspnoeic \[Medical Research Council (MRC) dyspnoea scale grade 4\] with an oxygen saturation of 88% on air. HRCT on day +57 showed dense central peribronchial consolidation with traction bronchiectasis and a perilobular pattern of consolidation in the periphery associated with pleuro-parenchymal distortion \[[Fig. 1](#fig1){ref-type="fig"}A(ii)\]. The patient was treated with 500 mg of intravenous methylprednisolone for three days followed by a prolonged reducing course of oral prednisolone over nine months, starting at 30 mg/day. Her dyspnoea improved and oxygen saturations increased to 96% on air. Allowing for breathing artefact, a Positron Emission Tomography (PET) CT on day +211 showed marked improvement in the bronchocentric and peripheral consolidation \[[Fig. 1](#fig1){ref-type="fig"}A(iii)\]. The patient\'s exercise tolerance returned to normal although pulmonary function tests (PFTs) on day +275 showed a persistent reduction in her transfer factor ([Table 2](#tbl2){ref-type="table"}).

### 1.1.2. Patient 2 {#sec1.1.2}

A 60 year old female non-smoker received a T deplete matched unrelated donor AlloHSCT for relapsed stage 4 follicular lymphoma, complicated by severe mucositis and acute skin graft versus host disease (GvHD). On day +22, PCR indicated systemic reactivation of CMV with a blood viral load of 22000 copies/ml. The patient developed cough and dyspnoea with an oxygen saturation of 88% on air. HCRT on day +26 showed diffuse bilateral ground glass opacification with nodular septal thickening compatible with viral infection \[[Fig. 1](#fig1){ref-type="fig"}B(i)\]. Treatment with ganciclovir resulted in rapid clinical improvement and the serum CMV PCR became negative. However, CMV reactivation recurred on day +118 and treatment had to be restarted. On day +130, the patient deteriorated with cough, dyspnoea (MRC grade 4), and an oxygen saturation of 89% on air. CMV blood viral load reached 26000 copies/ml on day +134 which represented the peak viral load. HRCT on day +136 demonstrated bilateral central and subpleural consolidation (with some traction bronchiectasis) and perilobular changes in the periphery consistent with an organising pneumonia \[[Fig. 1](#fig1){ref-type="fig"}B(ii)\]. The patient was commenced on a six month reducing course of prednisolone starting at 40 mg/day. Within three weeks her oxygen saturation returned to normal at rest, but she remained dyspnoeic on exertion (MRC grade 2) with a persistent defect in her transfer factor ([Table 2](#tbl2){ref-type="table"}). HRCT at day +322 showed residual band-like areas of consolidation, increased architectural distortion, traction bronchiectasis and volume loss consistent with a fibrosing organising pneumonia \[[Fig. 1](#fig1){ref-type="fig"}B(iii)\].

### 1.1.3. Patient 3 {#sec1.1.3}

A 15 year old female non-smoker received a T deplete matched unrelated donor AlloHSCT for acute lymphoblastic leukaemia. Although both patient and donor were CMV negative, on day +23 she developed pyrexia and PCR demonstrated CMV viraemia reaching a maximum of 69000 copies/ml by day +35. This was associated with progressive dyspnoea and hypoxia and an oxygen saturation of 88% on air. HCRT on day +42 showed widespread peribronchial consolidation with ground glass opacification and peripheral sparing \[[Fig. 1](#fig1){ref-type="fig"}C(i)\] compatible with a CMV pneumonitis. Treatment with intravenous foscarnet and pooled immunoglobulins caused a rapid improvement in her condition and blood CMV PCR became negative by day +60. On day +73, the dyspnoea (MRC grade 3) and hypoxaemia recurred. Repeat HRCT demonstrated dense consolidation forming perilobular bands, associated with pleuro-parenchymal distortion and traction bronchiectasis, consistent with a fibrosing organising pneumonia \[[Fig. 1](#fig1){ref-type="fig"}C(ii) & C(iii)\]. BAL was negative for bacteria, fungi and CMV-PCR. Transbronchial biopsy showed alveolar damage (likely infectious in origin) with mild interstitial fibrosis, focal fibroblastic reaction and congestion but no visible microorganisms or inclusion bodies. She was treated with 500mg of intravenous methylprednisolone for three days, followed by a reducing course of oral prednisolone starting at 30 mg/day. The dyspnoea improved with oxygen saturations increasing to 96% on air by day +95. The patient died on day +180 due to pulmonary haemorrhage complicating a probable bacterial pneumonia. A post-mortem was not performed.

### 1.1.4. Patient 4 {#sec1.1.4}

A 19 year old female non-smoker was treated with a T deplete sibling AlloHSCT for Fanconi Anaemia. On day +26 PCR demonstrated systemic reactivation of CMV with a maximum viral load of 15000 copies/ml by day +39. On day +41 she became dyspnoeic with an oxygen saturation of 90% on air. HCRT on day +42 showed diffuse bilateral ground glass opacification (slightly more dense on the left) with interlobular septal thickening compatible with a CMV pneumonitis \[[Fig. 1](#fig1){ref-type="fig"}D(i)\]. After treatment with intravenous foscarnet the patient clinically improved and CMV viral load became negative by day +59. On day +90 she developed cough and dyspnoea (MRC grade 4). Repeat HRCT on day +108 demonstrated dense bilateral peribronchial consolidation with perilobular changes in the periphery, traction bronchiectasis and architectural distortion consistent with a fibrosing organising pneumonia \[[Fig. 1](#fig1){ref-type="fig"}D(ii)\]. BAL on day +110 was negative for microorganisms including CMV, and transbronchial biopsy was not diagnostic showing minimal chronic inflammation with no CMV inclusions. The patient was treated with a reducing course of prednisolone starting at 40 mg daily remaining on low dose (2mg) long-term. Although her dyspnoea initially improved, she developed persistent exertional dyspnoea (MRC grade 3) associated with a severe mixed obstructive/restrictive lung function defect ([Table 2](#tbl2){ref-type="table"}). HRCT on day +202 showed further scarring with linear bands, progressive volume loss and architectural distortion \[[Fig. 1](#fig1){ref-type="fig"}D(iii)\].

### 1.1.5. Patient 5 {#sec1.1.5}

A 65 year old female non-smoker received a T deplete matched unrelated donor AlloHSCT for acute myeloid leukaemia. On day +74 she developed CMV reactivation with a maximum viral load of 1200000 copies/ml by day +88 and a CRP of 10.8 mg/L. This was associated with progressive dyspnoea and an oxygen saturation of 94% on air. HCRT on day +83 showed a diffuse bilateral ground glass infiltrate with thickening of the interlobular septa compatible with a CMV pneumonitis. \[[Fig. 1](#fig1){ref-type="fig"}E(i)\]. Treatment with intravenous foscarnet and ganciclovir reduced the CMV viral load to 740 copies/ml by day +100 and led to a slow clinical improvement. On day +104 her dyspnoea deteriorated (MRC grade 4), and repeat HRCT on day +110 demonstrated dense peribronchial consolidation with traction bronchiectasis and architectural distortion \[[Fig. 1](#fig1){ref-type="fig"}E(ii)\]. Treatment with three daily doses of 500mg intravenous methylprednisolone and a reducing course of oral prednisolone starting at 30 mg/day resulted in a normal oxygen saturation on air by day +124 and a normal exercise tolerance. Her transfer factor remained mildly reduced ([Table 2](#tbl2){ref-type="table"}).

2. Conclusion {#sec2}
=============

We describe five similar cases of a biphasic illness complicating the early period after a T cell deplete AlloHSCT. The initial phase consisted of CMV pneumonitis characterised by clinical evidence of pneumonia, systemic CMV infection, HRCT findings compatible with a viral pneumonitis, and clinical improvement following anti-CMV treatment. This was then followed by a second phase (57--136 days later) with clinical and radiological features consistent with a distinct form of organising pneumonia. The second phase was characterised by recurrence of severe dyspnoea and hypoxia, with a very different and distinct HRCT pattern comprised of central peribronchial consolidation, traction bronchiectasis and architectural distortion. When available, BAL showed no evidence of active infection. The clinical and radiological features during this phase resembled an atypical pattern of probable organising pneumonia. Diagnostic confirmation would have required a surgical lung biopsy, however this would have exposed the patients to excessive clinical risk. As expected with organising pneumonia, there was a significant clinical improvement following treatment with systemic corticosteroids. However, all surviving patients had evidence of at least some long term clinical, radiological and/or lung function abnormalities indicating chronic lung damage, with the expected restrictive pattern in three patients. The fourth patient had a mixed restrictive/obstructive lung function defect, a less common pattern for organising pneumonia. Unfortunately pre-transplant and pre-treatment for organising pneumonia lung function testing was not performed and therefore not available for comparison. The central peribronchial pattern of organising pneumonia described is an uncommon radiological pattern and the timing in these five cases would suggest a unique response to CMV pneumonitis. However, this is impossible to confirm and similar reactions could occur to other viral lung infections. Whether this complication is limited to allograft recipients remains unknown. It is also striking that all five cases were female, but the significance of this sex bias is unclear. Recognition that CMV pneumonitis can be complicated by a predominantly central bronchocentric pattern of organising pneumonia will allow early identification of future cases.
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![HRCT appearances for cases 1 (A), 2 (B), 3 (C), 4 (D) and 5 (E). The number above each panel refers to how many days after ASCT the HRCT scan was performed.](gr1){#fig1}

###### 

Case demography and clinical characteristics CT scan was obtained.

Table 1

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient                                                       Case 1                                                                               Case 2                                                                        Case 3                                                                                                                          Case 4                                                                     Case 5
  ------------------------------------------------------------- ------------------------------------------------------------------------------------ ----------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------
  Age                                                           28                                                                                   60                                                                            15                                                                                                                              19                                                                         65

  Sex                                                           Female                                                                               Female                                                                        Female                                                                                                                          Female                                                                     Female

  Underlying disease                                            Hodgkin\'s Lymphoma                                                                  Follicular\                                                                   Acute Lymphoblastic\                                                                                                            Fanconi Anaemia                                                            Acute Myeloid Leukaemia
                                                                                                                                                     Lymphoma                                                                      Leukaemia                                                                                                                                                                                                  

  Transplant conditioning                                       Carmustine\                                                                          Alemtuzumab\                                                                  Cyclophosphamide\                                                                                                               Fludarabine\                                                               Fludarabine\
                                                                Cytarabine\                                                                          Fludarabine\                                                                  Alemtuzumab\                                                                                                                    Melphalan\                                                                 Melphalan\
                                                                Etoposide\                                                                           Melphalan                                                                     TBI                                                                                                                             Alemtuzumab                                                                Alemtuzumab
                                                                Alemtuzumab\                                                                                                                                                                                                                                                                                                                                                                  
                                                                Melphalan                                                                                                                                                                                                                                                                                                                                                                     

  CMV serostatus patient/donor                                  Positive/Positive                                                                    Positive/Positive                                                             Negative/Negative                                                                                                               Positive/Negative                                                          Positive/Negative

  Date of CMV reactivation                                      Day +25                                                                              Day +22                                                                       Day +23                                                                                                                         Day +26                                                                    Day +74

  Maximum viral title (copies/ml)                               55000                                                                                26000                                                                         69000                                                                                                                           15000                                                                      1200000

  Diagnostic criteria for pneumonia                             Bilateral symmetrical ground glass infiltrates with interlobular septal thickening   Diffuse bilateral ground glass opacification with nodular septal thickening   Widespread bronchocentric consolidation with ground glass opacification and peripheral sparing                                  Diffuse bilateral ground infiltrates with interlobular septal thickening   Diffuse bilateral ground glass infiltrate with peripheral sparing and basal septal thickening

  Date of HRCT showing organising pneumonia                     Day +57                                                                              Day +136                                                                      Day +73                                                                                                                         Day+108                                                                    Day +110

  CMV titres changes (copies/ml)                                457                                                                                  Not detected                                                                  Not detected                                                                                                                    Not detected                                                               1000

  Treatment for organising pneumonia, steroids dose reduction   500 mg methylprednisolone × 3 days and reducing dose × 9 months                      40 mg/day prednisolone reducing dose × 6 months                               500mg of intravenous methylprednisolone × 3 days, followed by a reducing course of oral prednisolone × 3 months. Patient died   40 mg/day prednisolone remaining on low dose (2mg) longterm (2 years)      500mg methylprednisolone × 3 days and a reducing course of oral prednisolone × 12 months
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Recovery lung function testing data (none available for case 3 as the patient died).

Table 2

  ----------------------------------------------------------------------------
                        Case 1        Case 2       Case 4       Case 5
  --------------------- ------------- ------------ ------------ --------------
  Day tested            +275          +720         +730         +190

  FEV~1~ (%predicted)   2.85 (95%)    2.25 (96%)   0.97 (33%)   2.01 (105%)

  FVC (%predicted)      3.27 (95%)    2.64 (95%)   1.68 (50%)   2.42 (102%)

  TLC (%predicted)      4.91 (103%)   4.53 (89%)   3.27 (74%)   4.64 (102%)\

  TLCO (% predicted)    4.70 (53%)    3.46 (45%)   3.67 (42%)   4.09 (58%)

  KCO (% predicted)     1.29 (69%)    0.90 (60%)   1.75 (89%)   1.51 (75%)
  ----------------------------------------------------------------------------
